|Day's Range||582.35 - 609.30|
|52 Week Range||564.00 - 854.95|
|PE Ratio (TTM)||18.61|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Sun Pharmaceutical Industries Ltd., India’s largest drugmaker, warned investors that sales could decline in the coming year amid downward pressure on generic-drug prices in the U.S. and regulatory issues ...
India's big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official. The lengthy timeline is a concern not only in India but around the world, as India's pharmaceutical firms supply a third of the drugs sold in the United States and a large percentage in other countries.
The U.S. Food and Drug Administration noted incomplete laboratory records among potential manufacturing violations it observed during an inspection of Sun Pharmaceutical Industries Ltd.’s Dadra unit this ...